Trial site
Alrijne Zorggroep Stichting
Leiderdorp, 2353 GA, NetherlandsNot linked to an institution yet
- 22running trials
- 1closed trial
The trials here
What the 23 trials at this site are about, from their registry records.
- Phase
- Phase 316 trials
- Phase 47 trials
- Status
- Recruiting13 trials
- Active, not recruiting8 trials
- Completed1 trial
- Not yet recruiting1 trial
- Lead sponsor
- Amsterdam UMC Stichting3 trials
- Leiden University Medical Center2 trials
- Novo Nordisk A/S2 trials
- Sanofi2 trials
- Amsterdam UMC1 trial
- and 13 more
Running trials
Recruiting
ALBUMINUS: Dose reduction of human albumin during large-volume paracentesis in patients with cirrhosis
2026-526167-38-00· Phase 4· Amsterdam UMC Stichting· Source
Not yet recruiting
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· Phase 3· Novo Nordisk A/S· Source
Recruiting
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
NCT07626411· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001· Phase 3· Novo Nordisk A/S· Source
Recruiting
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00· Phase 3· Novartis Pharma AG· Source
Not yet recruiting
Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy
NCT07486687· Phase 3· The Netherlands Cancer Institute· Source
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390· Phase 3· Eli Lilly and Company· Source
Recruiting
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
2023-510294-34-00· Phase 3· University Of Cologne· Source
Active, not recruiting
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347· Phase 3· Sanofi· Source
Recruiting
Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial
2024-513092-40-00· Phase 4· Stichting Radboud universitair medisch centrum· Source
Recruiting
inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT
NCT06581965· Phase 4· Leiden University Medical Center· Source
Active, not recruiting
Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS)
NCT04225312· Phase 4· Amsterdam UMC Stichting· Source
Active, not recruiting
DUTCH Weight Control in Atrial Fibrillation Study
NCT06184633· Phase 4· Rijnstate Hospital· Source
Recruiting
DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer
NCT06275958· Phase 3· Leiden University Medical Center· Source
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288· Phase 3· Boehringer Ingelheim· Source
Recruiting
FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)
NCT06187441· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Recruiting
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT05950945· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS
2022-502664-21-00· Phase 4· Amsterdam UMC· Source
Recruiting
An European multinational study of a personalized approach of human albumin administration in patients with cirrhosis of the liver and complications
2022-501006-34-01· Phase 3· Odense University Hospital· Source
Active, not recruiting
The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
NCT05374291· Phase 3· University Medical Center Groningen· Source
Active, not recruiting
Personalized dosing of ocrelizumab in MS
2024-513193-22-00· Phase 4· Amsterdam UMC Stichting· Source
Recruiting
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
NCT04774159· Phase 3· Population Health Research Institute· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error